K

Kilitch Drugs (India) Ltd
NSE:KILITCH

Watchlist Manager
Kilitch Drugs (India) Ltd
NSE:KILITCH
Watchlist
Price: 323.15 INR -0.46%
Market Cap: 5.2B INR
Have any thoughts about
Kilitch Drugs (India) Ltd?
Write Note

Gross Margin
Kilitch Drugs (India) Ltd

34.8%
Current
38%
Average
48.4%
Industry

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
34.8%
=
Gross Profit
547.4m
/
Revenue
1.6B

Gross Margin Across Competitors

Country IN
Market Cap 5.2B INR
Gross Margin
35%
Country JP
Market Cap 776 550.9T JPY
Gross Margin
-3%
Country US
Market Cap 755.8B USD
Gross Margin
81%
Country UK
Market Cap 440.4B GBP
Gross Margin
56%
Country DK
Market Cap 2.7T DKK
Gross Margin
85%
Country US
Market Cap 351.1B USD
Gross Margin
69%
Country US
Market Cap 251.8B USD
Gross Margin
77%
Country CH
Market Cap 200.1B CHF
Gross Margin
73%
Country UK
Market Cap 161.8B GBP
Gross Margin
82%
Country CH
Market Cap 171.5B CHF
Gross Margin
75%
Country US
Market Cap 151.5B USD
Gross Margin
71%
No Stocks Found

Kilitch Drugs (India) Ltd
Glance View

Market Cap
5.2B INR
Industry
Pharmaceuticals

Kilitch Drugs (India) Ltd. engages in the manufacture and sale of pharmaceuticals, medicinal chemical, and botanical products. The company is headquartered in Mumbai, Maharashtra. The company is primarily engaged in the development, manufacturing, and marketing of finished dosages. The Company’s products include parenteral solutions, effervescent, nutritional products, and medical device. Its products categories include urinary alkalizer, cephalosporins products, gastroenterology, non steroidal anti-inflammatory drugs (NSAIDs), anticonvulsant/antiepileptic, adrenergic agonist, neurotonic, muscle relaxant/stimulant, aminoglycosides, anti-infective, anti-inflammatory, anti-malarials, anti-hypertensive, anaesthetic, uterine stimulants. Its parenteral solutions include neurotonic, veterinary products, metered nasal drops, vaccines, oncology, and ophthalmic products. Its effervescent products include Roipar, Duregra, And Roivit. The firm offers nutritional products, such as Celtine. The firm also offers medical devices, such as C-Seal.

KILITCH Intrinsic Value
251.63 INR
Overvaluation 22%
Intrinsic Value
Price
K

See Also

Discover More
What is Gross Margin?

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
34.8%
=
Gross Profit
547.4m
/
Revenue
1.6B
What is the Gross Margin of Kilitch Drugs (India) Ltd?

Based on Kilitch Drugs (India) Ltd's most recent financial statements, the company has Gross Margin of 34.8%.